Prev: INFO: Hepatitis C Virus: From Oxygen Free Radicals to Hepatocellular Carcinoma
Next: Ping greyhackles re Iron and virons
From: Thomas Wagner on 23 Jan 2008 11:19
[...]
In one study, Dr. Alessandra Mangia from "Casa Sollievo della
Sofferenza" Hospital, San Giovanni Rotondo, Italy, and colleagues
treated 696 patients with HCV genotype 1 with peginterferon alfa-2a (180
g/week) or peginterferon alfa-2b (1.5 g/kg/week), plus ribavirin (1,000
to 1,200 mg/day). Patients were randomized to treatment for 48 weeks
(the standard treatment group; n = 237) or for 24, 48 or 72 weeks if
HCV-RNA was undetectable at 4, 8, or 12 weeks, respectively (the
variable treatment group; n = 459).

According to the investigators, results showed "equivalent rates of
lasting viral clearance after therapy administered for the standard
48-week length or a variable duration tailored on the first undetectable
HCV RNA during the initial 12 weeks of therapy."

Nearly 49% of patients receiving variable treatment based on detectable
HCV RNA achieved a sustained virologic response, compared with 45% of
patients in the standard treatment group (p = 0.37), Dr. Mangia and
colleagues report.
[...]

Full text at http://www.medscape.com/viewarticle/568842
(Requires free registration)

Thomas
--
To reach me, complete my last name in the address.
 | 
Pages: 1
Prev: INFO: Hepatitis C Virus: From Oxygen Free Radicals to Hepatocellular Carcinoma
Next: Ping greyhackles re Iron and virons